Krka, d. d. (KRK.WA)
- Previous Close
744.00 - Open
746.00 - Bid 744.00 x --
- Ask 748.00 x --
- Day's Range
746.00 - 750.00 - 52 Week Range
534.00 - 776.00 - Volume
162 - Avg. Volume
95 - Market Cap (intraday)
23B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
14.92 - EPS (TTM)
50.15 - Earnings Date May 15, 2025
- Forward Dividend & Yield 32.24 (4.33%)
- Ex-Dividend Date Jul 23, 2024
- 1y Target Est
--
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, infections, oncology, and other diseases. It provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others. In addition, the company offers animal health products comprising analgesics antimicrobials, antiparasitics, disinfectants, vitamins, and minerals. Further, the company provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.
www.krka.biz11,308
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KRK.WA
View MorePerformance Overview: KRK.WA
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRK.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRK.WA
View MoreValuation Measures
Market Cap
22.85B
Enterprise Value
20.46B
Trailing P/E
14.83
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.81
Price/Book (mrq)
2.44
Enterprise Value/Revenue
2.51
Enterprise Value/EBITDA
9.29
Financial Highlights
Profitability and Income Statement
Profit Margin
18.69%
Return on Assets (ttm)
9.47%
Return on Equity (ttm)
16.12%
Revenue (ttm)
1.91B
Net Income Avi to Common (ttm)
356.99M
Diluted EPS (ttm)
50.15
Balance Sheet and Cash Flow
Total Cash (mrq)
589.24M
Total Debt/Equity (mrq)
0.59%
Levered Free Cash Flow (ttm)
245.1M